European Commission clears Abbott acquisition of Alere, but will it proceed?

26 January 2017

The European Commission has granted clearance for US drugmaker Abbott Laboratories (NYSE: ABT) to acquire Alere (NYSE: ALR), a maker of rapid diagnostics.

In order to address the competition concerns identified by the Commission, Abbott offered to:

fully divest Alere's global Epoc business, including its manufacturing site in Ottawa, Canada;
fully divest Alere's global Triage business, including its manufacturing site in San Diego, USA. This business also manufactures essential inputs for the production of BNP reagents for Danaher laboratory devices, which are included in the divestment; and
fully divest the Alere BNP reagents business that commercialises a BNP test with Danaher.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK